IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Portfolio Pulse from
IN8bio, Inc. (Nasdaq: INAB) reported its Q3 2024 financial results, highlighting that all Acute Myeloid Leukemia patients in the INB-100 trial remain in complete remission. The company received FDA guidance for a future trial and closed a private placement for $11.6 million, extending its cash runway through 2025.
November 12, 2024 | 9:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
IN8bio reported strong Q3 2024 results with all AML patients in the INB-100 trial in complete remission. The company received FDA guidance for future trials and secured $11.6M in funding, extending its cash runway through 2025.
The news highlights significant clinical success with 100% remission in AML patients, which is a strong positive indicator for IN8bio's INB-100 trial. The FDA guidance for future trials and the successful private placement further strengthen the company's financial and regulatory position, likely boosting investor confidence and positively impacting the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100